Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): Safety, efficacy and improved secondary surgical resectability

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 339-348

  Lévi, Francis ^a,b   Karaboué, Abdoulaye ^a,b   Gorden, Lee ^a,c   Innominato, Pasquale Fabio ^a,b   Saffroy, Raphael ^a   Giacchetti, Sylvie ^a,b   Hauteville, Dominique ^a   Guettier, Catherine ^a   Adam, René ^a,b   Bouchahda, Mohamed ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Cetuximab; Chronotherapy; Circadian clocks; Liver resection; Metastatic colorectal cancer; Neoadjuvant chemotherapy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ACNE; ADD ON THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHRONOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HYPOMAGNESEMIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS INHIBITION; METASTASIS POTENTIAL; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SENSORY NEUROPATHY; SKIN TOXICITY; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENE AMPLIFICATION; GENETICS; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; ONCOGENE RAS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG CHRONOTHERAPY; FEMALE; FLUOROURACIL; GENE AMPLIFICATION; GENES, RAS; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79953782046     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1327-8     Document Type: Article

References (45)

1. Giacchetti S, Itzhaki M, Gruia G et al (1999) Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10:663-669 (Pubitemid 29342371)
2. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-657
3. Folprecht G, Grothey A, Alberts S et al (2005) Neoadjuvant treatmentofunresectable colorectalliver metastases: correlation between tumour response and resection rates. Ann Oncol 16:1311-1319 (Pubitemid 41158476)
4. Adam R, Aloia T, Lévi F et al (2007) Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 25:4593-4602 (Pubitemid 350035318)
5. Jonker DJ, O'Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048 (Pubitemid 350106711)
6. Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311-2319
7. Pessino A, Artale S, Sciallero S et al (2008) First-line singleagent cetuximab in patients with advanced colorectal cancer. Ann Oncol 19(4):711-716 (Pubitemid 351467382)
8. Van Cutsem E, Köhne CH, Hitre e et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417
9. Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:391-392
10. Lenz HJ, Van Cutsem EV, Khambata-Ford S et al (2006) Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914-4921 (Pubitemid 46630920)
11. Shim KS, Kim KH, Park BW et al (1998) Increased serum levels of transforming growth factor-alpha in patients with colorectal cancer. Dis Colon Rectum 41(2):219-224
12. Rich T, Innominato PF, Boerner J et al (2005) Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 11:1757-1764 (Pubitemid 40471837)
13. Kramer A, Yang FC, Snodgrass P et al (2001) Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science 294:2511-2515 (Pubitemid 34027284)
14. Snodgrass-Belt P, Gilbert JL, Davis FC (2005) Central administration of transforming growth factor-alpha and neuregulin-1 suppress active behaviors and cause weight loss in hamsters. Brain Res 1038:171-182 (Pubitemid 40332682)
15. Lévi F, Schibler U (2007) Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol 47:593-628
16. Reddy AB, Karp NA, Maywood ES et al (2006) Circadian orchestration of the hepatic proteome. Curr Biol 16:1107-1115 (Pubitemid 43815745)
17. Iurisci I, Filipski E, Reinhardt J et al (2006) Improved tumor control through circadian clock induction by Seliciclib, a cyclindependent kinase inhibitor. Cancer Res 66:10720-10728 (Pubitemid 44876967)
18. Levi FA, Zidani R, Vannetzel JM et al (1994) Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multiinstitutional trial. J Natl Cancer Inst 86:1608-1617 (Pubitemid 24336347)
19. Levi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 350:681-686 (Pubitemid 27371165)
20. Giacchetti S, Bjarnason G, Garufi C et al (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24:3562-3569 (Pubitemid 46630527)
21. Lévi F, Focan C, Karaboué A et al (2007) Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev 59:1015-1035 (Pubitemid 47542287)
22. Folprecht G, Gruenberger T, Bechstein WO et al (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1):38-47
23. Perez-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235-5246 (Pubitemid 46224035)
24. Tejpar S, Peeters M, Humblet y et al (2007) Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. J Clin Oncol 25 (Suppl 18 S): 172s (Abstr 4037)
25. Vincenzi B, Santini D, Rabitti C et al (2006) Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer 94:792-797
26. Souglakos J, Kalykaki A, Vamvakas L et al (2007) Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol 18:305-310 (Pubitemid 46323098)
27. Pfeiffer P, Nielsen D, Bjerregaard J et al (2008) Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 19:1141-1145 (Pubitemid 351796340)
28. Gholam D, Giacchetti S, Brézault-Bonnet C et al (2006) Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-fluorouracil as ambulatory salvage therapy in patients with Irinotecan-and Oxaliplatin-resistant metastatic colorectal cancer. Oncologist 11:1072-1080 (Pubitemid 44788398)
29. Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J (2010) Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50:375-419
30. Adam R, Wicherts DA, de Haas RJ et al (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27:1829-1835
31. Tabernero J, Van Cutsem E, Díaz-Rubio E, et al (2007) Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 25:5225-5232 (Pubitemid 350232254)
32. Lièvre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379 (Pubitemid 351171687)
33. Cappuzzo F, Varella-Garcia M, Finocchiaro G et al (2008) Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 99:83-89 (Pubitemid 351920237)
34. Chung KY, Shia J, Kemeny NE et al (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810 (Pubitemid 46211358)
35. Hebbar M, Wacrenier A, Desauw C et al (2006) Lack of usefulness of epidermal growth factor-receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17:855-857 (Pubitemid 44310182)
36. Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279-286 (Pubitemid 40590264)
37. Cappuzzo F, Finocchiaro G, Rossi e et al (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19:717-723 (Pubitemid 351461042)
38. Sartore-Bianchi A, Moroni M, Veronese S et al (2007) Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 25:3238-3245 (Pubitemid 47325607)
39. Milano G, Etienne-Grimaldi MC, Dahan L et al (2008) Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann Oncol 19:2033-2038
40. Scartozzi M, Bearzi I, Mandolesi A et al (2009) Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 9:303
41. Haus E, Dimitriu L, Nicolau GY et al (2001) Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth actor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer. Chronobiol Int 18:709-727 (Pubitemid 32929215)
42. Lévi F, Filipski E, Iurisci I et al (2007) Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp Quant Biol 72:465-475
43. Mormont MC, Waterhouse J, Bleuzen P et al (2000) Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6:3038-3045 (Pubitemid 30637726)
44. Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchatti S, Coudert B, Iacobelli S, Genet D, Tampellini M, Chollet P, Lentz MA, Mormont MC, Levi F, Bjarnason GA, Chronotherapy Group of the European Organization for Research and Treatment of Cancer (2009) Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res 69:4700-4707
45. Iurisci I, Rich T, Lévi F et al (2007) Relief of symptoms after Gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer. J Clin Oncol 25: e17-e19